Drugs in ATC Class C05BB

Up to Top Level ATC Classes

Up to C - Cardiovascular system

Up to C05 - VASOPROTECTIVES

Up to C05B - ANTIVARICOSE THERAPY

Drugs in ATC Class: C05BB - Sclerosing agents for local injection

Tradename	Generic Name
ASCLERA	polidocanol
VARITHENA	polidocanol
TRAVERT 10% IN PLASTIC CONTAINER	invert sugar
SODIUM TETRADECYL SULFATE	sodium tetradecyl sulfate
SOTRADECOL	sodium tetradecyl sulfate

C05BB Sclerosing Agents for Local Injection: Market Dynamics and Patent Landscape

Last updated: July 31, 2026

The C05BB market is mature, fragmented and largely generic at the active-ingredient level. The principal commercial products are polidocanol, sodium tetradecyl sulfate and ethanolamine oleate, used mainly for sclerotherapy of varicose veins, venous malformations and selected vascular lesions. Core composition patents have generally expired. Current differentiation depends on foam delivery, concentration, packaging, manufacturing controls, clinical labeling and physician adoption.

The strongest remaining commercial position is associated with proprietary polidocanol foam products, particularly Varithena. Generic injectable sclerosing agents face limited composition-of-matter barriers, but a direct substitute for a branded foam product may encounter formulation, device, regulatory and clinical-development hurdles.

What drugs are classified under ATC C05BB?

ATC C05BB covers sclerosing agents administered by local injection. The classification is pharmacologic and commercial, not a patent or regulatory category. Products within the class differ in mechanism, formulation, concentration and approval status across jurisdictions.

Active ingredient	Common commercial identity	Typical use	Principal market status
Polidocanol, also called lauromacrogol 400	Asclera; Varithena; numerous non-U.S. products	Varicose veins and venous insufficiency	Branded liquid and foam products; generics and compounded products in several markets
Sodium tetradecyl sulfate	Sotradecol and generic products	Varicose veins and venous lesions	Long-established injectable; composition protection largely expired
Ethanolamine oleate	Ethamolin and regional products	Varices and vascular lesions	Older injectable with regional availability
Hypertonic saline and related agents	Compounded or regional products	Small-vein sclerotherapy	Generally outside the main branded FDA market
Other regional sclerosants	Various	Varicose veins, hemorrhoids or vascular malformations	Marketed under country-specific approvals

The FDA-approved U.S. products with the greatest commercial relevance are Asclera, a polidocanol injection, and Varithena, a polidocanol injectable foam. The FDA label for Asclera covers treatment of uncomplicated spider veins and uncomplicated reticular veins. Varithena is approved for treatment of incompetent veins and improvement of symptoms related to superficial venous reflux [1, 2].

How large is the C05BB sclerotherapy market?

Public market data usually combine sclerosing agents with broader varicose-vein devices, vascular intervention products or aesthetic injectables. Stand-alone revenue figures for ATC C05BB are therefore limited.

The commercial market has four demand drivers:

1. The prevalence of chronic venous disease and varicose veins.
2. Growth in office-based and ambulatory vein procedures.
3. Physician migration from liquid sclerotherapy toward ultrasound-guided foam.
4. Reimbursement and procedural capacity in vascular, dermatology and phlebology practices.

The market is split between low-priced injectable products and premium branded foam systems. Liquid sodium tetradecyl sulfate and polidocanol compete primarily on price, availability, concentration range and physician familiarity. Varithena competes on standardized foam preparation, delivery convenience and clinical positioning rather than on active-ingredient exclusivity alone.

Which companies sell C05BB products?

Company	Product or asset	Active ingredient	Commercial role
Boston Scientific	Varithena	Polidocanol	Proprietary injectable foam system
Merz North America	Asclera	Polidocanol	Branded liquid injectable
Regional generic manufacturers	Polidocanol and sodium tetradecyl sulfate products	Various	Price-based competition
Compounding pharmacies	Foam and liquid preparations	Various	Local or specialty supply, subject to applicable regulatory rules
Hospital and specialty distributors	Sotradecol and related products	Sodium tetradecyl sulfate	Distribution and supply-chain access

Boston Scientific obtained BTG, the company associated with Varithena, in 2019. Merz markets Asclera in the United States. Product ownership and distribution arrangements differ by country [3, 4].

What patents protect polidocanol and sodium tetradecyl sulfate?

The active ingredients are old pharmaceutical substances. Their primary composition-of-matter patents have expired or are not commercially meaningful in the United States. Current patent value is concentrated in formulations, foam generation, delivery systems, manufacturing methods and specific therapeutic uses.

Patent category	Polidocanol	Sodium tetradecyl sulfate
Active-ingredient composition	Generally expired or unavailable as a meaningful barrier	Generally expired
Liquid injectable formulation	Mostly mature and vulnerable to generic competition	Mostly mature and vulnerable to generic competition
Foam formulation	More significant, particularly for standardized injectable foam	Less commercially prominent
Device and delivery system	Relevant to proprietary foam products	Usually limited
Method of treatment	May support secondary protection where claim scope is enforceable	Usually narrow or expired
Manufacturing and quality controls	Potentially relevant to regulatory approval and supply	Potentially relevant to supply, but rarely a strong exclusion right

A patent review should separate three rights: patents listed in the FDA Orange Book, patents that may be asserted in litigation, and patents that create a practical manufacturing or regulatory barrier without being listed for a drug product.

What formulations are protected by Varithena patents?

Varithena is a proprietary polidocanol foam product. Its commercial differentiation is based on a prefilled presentation and controlled preparation of injectable foam rather than on a new sclerosing active ingredient.

The relevant technical features include:

• Polidocanol concentration and excipient composition.
• Foam generation and gas-liquid characteristics.
• Foam stability and bubble-size distribution.
• Prefilled container configuration.
• Preparation and administration steps.
• Compatibility of the product with injection equipment.
• Manufacturing controls that support reproducible foam quality.

These features can create patent and regulatory barriers even when polidocanol itself is off patent. A competitor may avoid a composition claim but still need to establish equivalent pharmaceutical quality, stability, usability and clinical performance.

The legal strength of a foam patent depends on claim construction, prosecution history, expiration dates, terminal disclaimers, patent-term adjustment, and whether the claims cover the marketed product as approved. Patent families should be reviewed by jurisdiction rather than treated as a single global right.

What is the Orange Book status of Asclera and Varithena?

The Orange Book is the principal U.S. source for patents and regulatory exclusivity associated with approved drug products. Patent listings can change, and an Orange Book entry does not establish that every listed claim is valid or infringed.

Asclera and Varithena require separate reviews because they are different approved products despite sharing polidocanol as the active ingredient.

Product	FDA application	Dosage form	Regulatory distinction
Asclera	NDA 021201	Injection	Liquid polidocanol for spider and reticular veins
Varithena	NDA 205098	Injectable foam	Polidocanol foam for incompetent veins and superficial venous reflux

The commercial importance of a listing depends on:

• Whether the patent is still unexpired.
• Whether the patent claims the approved product, formulation or method of use.
• Whether a generic applicant must certify under Paragraph IV.
• Whether the listed patent carries pediatric exclusivity or another extension.
• Whether the FDA has accepted a certification and whether litigation triggers a stay.

For products with old active ingredients, regulatory exclusivity may be more important than composition patents. Varithena obtained approval in 2013 and benefited from the regulatory protection applicable to a new drug application, but that exclusivity does not permanently block later abbreviated or hybrid competition [2, 5].

When does C05BB lose exclusivity?

There is no single C05BB exclusivity date. Each product has its own FDA approval history, Orange Book listings, patent terms and regulatory pathway.

Asclera exclusivity and patent timing

Asclera was approved in the United States in 2010. Its active ingredient, polidocanol, was already established internationally and did not create a durable composition-of-matter barrier. The principal commercial protection has therefore depended on the approved formulation, labeling, brand recognition and supply.

A generic entrant could seek approval through an ANDA if it can demonstrate pharmaceutical equivalence and meet the applicable requirements. A product with a different concentration, formulation or indication may require a different regulatory strategy.

Varithena exclusivity and patent timing

Varithena was approved in 2013. Its risk profile is different because it is a standardized injectable foam rather than a conventional liquid injection. A competitive product may need to address:

• Foam-generation technology.
• Container and administration configuration.
• Product stability.
• Sterility assurance.
• Foam-performance specifications.
• Clinical use in the approved venous-reflux population.

The relevant patent expiry date is the expiry date of each enforceable patent that covers the approved product or a required method of use. A single family-level date is not sufficient for transaction or litigation analysis.

Which companies are challenging C05BB products?

Publicly visible competitive pressure comes mainly from generic manufacturers, regional manufacturers and compounded-product suppliers. The market does not have the same high-volume Paragraph IV activity seen in blockbuster oral drugs.

The most likely challengers are:

• Generic injectable manufacturers seeking approval for polidocanol or sodium tetradecyl sulfate.
• Specialty manufacturers developing ultrasound-guided foam products.
• Compounding pharmacies supplying physician-prepared foam.
• Medical-device companies pairing sclerosing agents with delivery systems.
• European and Asian manufacturers using country-specific hybrid or national approval pathways.

A Paragraph IV challenge against a branded foam product would be commercially meaningful only if the challenger can obtain approval for a product close enough to the branded indication and presentation to compete for the same procedures. A liquid generic may enter without directly displacing a standardized foam product.

What patent litigation affects the C05BB market?

C05BB litigation risk is generally lower than in newer therapeutic classes because the principal actives are old and the market is relatively small. The more credible disputes concern:

• Foam composition and stability.
• Delivery devices and prefilled containers.
• Manufacturing processes.
• Method-of-use claims for specific venous anatomy.
• False patent certification or abbreviated-application disputes.
• Trade secrets involving manufacturing specifications.
• Product substitution and advertising claims.

A patent dispute involving a foam product may affect market entry without eliminating competition in liquid polidocanol or sodium tetradecyl sulfate. Product-by-product claim mapping is required because a patent covering foam preparation may not cover a conventional liquid injection.

What generic entry risks exist for C05BB products?

Liquid polidocanol

Liquid polidocanol has high generic-entry exposure. The active ingredient is old, the dosage form is conventional, and physician familiarity with the product reduces switching friction. Commercial barriers are mainly manufacturing, sterile injectable quality, distribution and reimbursement.

Sodium tetradecyl sulfate

Sodium tetradecyl sulfate also has high generic-entry exposure. Supply interruptions can create temporary pricing power because the market relies on a limited number of sterile injectable suppliers. That advantage is operational rather than patent-based.

Polidocanol foam

Polidocanol foam has medium generic-entry exposure. The active ingredient is vulnerable, but the product-specific technology is more complex. A challenger may need to select among:

1. An ANDA targeting the same product.
2. A 505(b)(2) application relying partly on existing data.
3. A new NDA for a materially different foam system.
4. A device-drug combination strategy.
5. A compounded or physician-prepared product, where legally available.

The timing and cost of entry will depend on the chosen pathway and the scope of any unexpired listed patents.

How strong is the C05BB patent estate?

Segment	Patent strength	Main reason
Sodium tetradecyl sulfate liquid injection	Low	Old active, mature formulation, limited differentiation
Polidocanol liquid injection	Low to moderate	Brand and labeling advantages exceed core patent value
Polidocanol injectable foam	Moderate	Formulation, preparation and delivery claims may remain relevant
Physician-prepared foam	Low at composition level	Product may avoid branded claims but faces regulatory and quality limits
Sclerotherapy delivery devices	Moderate in selected configurations	Device patents can protect workflow and administration
Manufacturing processes	Moderate	Process claims may create supply barriers but are difficult to detect and enforce

The strongest assets are not necessarily the oldest patents. A later-filed formulation patent with narrow but product-specific claims may have more practical value than a broad expired composition patent.

How does C05BB compare with competing venous treatments?

Sclerotherapy competes with endovenous thermal ablation, nonthermal adhesive systems, mechanochemical ablation and surgical treatment.

Treatment	Main commercial advantage	Competitive pressure on C05BB
Liquid sclerotherapy	Low equipment cost and office-based use	Baseline competitor within C05BB
Foam sclerotherapy	Treats larger veins with ultrasound guidance	Supports premium product positioning
Radiofrequency ablation	Durable treatment for selected truncal veins	Reduces use in anatomy suitable for catheter ablation
Endovenous laser	Established thermal ablation option	Competes for procedural referrals
Cyanoacrylate closure	Nonthermal and catheter-based	Competes for patients seeking minimally invasive treatment
Mechanochemical ablation	Reduced thermal injury concerns	May displace some foam procedures

The competitive threat is anatomical and procedural. Sclerosing agents remain attractive for smaller veins, residual veins, tributaries and patients who are not ideal candidates for catheter-based treatment.

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are sterile injectable production, control of impurities, container closure, stability, particulate limits and reliable supply of pharmaceutical-grade active ingredient.

Foam products add requirements for:

• Reproducible foam density.
• Controlled bubble size.
• Stability during the labeled administration window.
• Consistent gas composition.
• Device compatibility.
• Sterility and container integrity.
• Human-factors validation for preparation and injection.

These requirements can delay entry even when patent protection is weak. They also create licensing opportunities around foam generators, prefilled syringes, valves, connectors and automated preparation systems.

What licensing deals affect the C05BB market?

The most important publicly disclosed transaction affecting the class was Boston Scientific's acquisition of BTG, completed in 2019. The transaction transferred control of BTG's interventional medicine portfolio, including Varithena, to Boston Scientific [3].

The sector has limited evidence of broad platform licensing for the underlying active ingredients. Commercial arrangements are more likely to involve:

• Regional distribution rights.
• Contract manufacturing.
• Device supply.
• Co-promotion.
• Compounding or specialty pharmacy supply.
• Acquisition of venous-intervention portfolios.

Licensing value is therefore concentrated in branded foam technology, distribution access and procedural platforms rather than in polidocanol or sodium tetradecyl sulfate chemistry.

What is the geographic coverage of C05BB patents and approvals?

U.S. patent and regulatory risk differs from Europe and other markets. Polidocanol is widely established in European venous practice under the name lauromacrogol 400. National approvals, centralized European procedures, supplementary protection certificates and local formulation claims may create different entry dates.

Key geographic considerations include:

• U.S. Orange Book-listed patents and FDA exclusivity.
• European patent validation and national litigation.
• Supplementary protection certificates, where applicable.
• Canadian, Japanese and Australian product registrations.
• Local rules for physician-prepared foam.
• Import controls for sterile injectables.
• Country-specific reimbursement and substitution policies.

A global freedom-to-operate review must examine patent families, national status, regulatory labels and local use restrictions. U.S. expiration dates cannot be applied automatically to Europe or Asia.

What generic launch scenarios are most likely?

Scenario 1: Low-cost liquid generic entry

A generic manufacturer enters with polidocanol or sodium tetradecyl sulfate injection. Price erosion is substantial in commodity channels, while branded products retain use where physicians value supply reliability or established labeling.

Scenario 2: Limited substitution for Varithena

A liquid generic enters but does not replicate the standardized foam presentation. Varithena retains a premium in procedures requiring predictable foam preparation, while liquid products compete in smaller-vein treatment.

Scenario 3: Competing injectable foam

A challenger develops a foam product through an ANDA, 505(b)(2) application or NDA. The principal risks are patent certification, clinical comparability, device compatibility and manufacturing scale.

Scenario 4: Supply-constrained market

A sterile injectable manufacturer experiences a shortage or manufacturing interruption. Prices rise temporarily, but the increase reflects capacity constraints rather than durable patent exclusivity.

Key Takeaways

• C05BB contains mature sclerosing agents dominated by polidocanol and sodium tetradecyl sulfate.
• Core active-ingredient patent protection is generally exhausted.
• Liquid injectables have high generic-entry exposure.
• Varithena has the strongest product-specific differentiation because it is a standardized injectable foam.
• Formulation, foam-generation, container and delivery patents matter more than composition patents.
• Asclera and Varithena must be analyzed separately under FDA and Orange Book rules.
• Boston Scientific is the principal commercial company associated with Varithena after its acquisition of BTG.
• Merz is the principal U.S. branded company associated with Asclera.
• Generic liquid entry may not materially displace a branded foam product.
• Manufacturing quality, sterile capacity and regulatory pathway selection are major practical barriers.
• Litigation risk is concentrated in product-specific foam and delivery claims rather than old active-ingredient patents.

FAQs

Is polidocanol still patent protected?

Polidocanol itself is an old active ingredient and does not provide a meaningful current composition-of-matter barrier in the U.S. Remaining protection, where present, is more likely to concern formulations, foam systems, delivery devices or methods of use.

Can a generic liquid polidocanol product replace Varithena?

Not automatically. A liquid product may be therapeutically useful for overlapping procedures but does not necessarily have the same dosage form, preparation method, indication, administration characteristics or regulatory substitutability as Varithena.

Is sodium tetradecyl sulfate a biologic or biosimilar product?

No. Sodium tetradecyl sulfate is a small-molecule pharmaceutical. Biosimilar rules do not apply. A competing product would generally use a generic or other small-molecule FDA pathway.

What is the principal patent risk for a new sclerotherapy foam?

The principal risks are claims covering foam composition, bubble characteristics, preparation equipment, prefilled containers, administration methods and manufacturing controls. Freedom-to-operate analysis must review both drug patents and device patents.

Does an Orange Book listing guarantee delayed generic entry?

No. A listing can require a generic applicant to make a patent certification and can lead to patent litigation. It does not establish patent validity, infringement or ultimate enforceability.

References

1. U.S. Food and Drug Administration. (2023). Asclera (polidocanol injection) prescribing information.
2. U.S. Food and Drug Administration. (2023). Varithena (polidocanol injectable foam) prescribing information.
3. Boston Scientific Corporation. (2019). Boston Scientific completes acquisition of BTG plc.
4. Merz North America, Inc. (2023). Asclera product information.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. World Health Organization Collaborating Centre for Drug Statistics Methodology. (2024). ATC/DDD index: C05BB Sclerosing agents for local injection.